William Demant Invest

What William Demant Invest does

William Demant Invest A/S is a private Danish evergreen investment holding company founded in 2004 and headquartered in Smørum, Denmark. It operates as the investment vehicle of the charitable William Demant Foundation (established 1957) and holds majority and significant minority stakes in listed healthcare and MedTech companies, functioning as a long-term strategic investor rather than a typical operating business. The company itself does not generate operating revenue; its economic model is based on long-duration ownership of portfolio companies and the appreciation of those stakes.

The portfolio spans hearing healthcare (Demant A/S, ~55-60% ownership, the flagship investment and the world's second-largest hearing aid company with brands including Oticon, Bernafon and EPOS, generating approximately DKK 23 billion in annual revenue across 22,000 employees), non-invasive orthopaedics (Embla Medical, 51%), surface-guided radiation therapy (Vision RT, 93%, UK), reproductive medicine/IVF (Vitrolife, ~30%, Sweden), digital hematology microscopy (CellaVision, ~20%, Sweden), ophthalmological devices (Revenio, ~24%, Finland), tactical communications (INVISIO, 20%, Sweden), Danish real estate (Jeudan, 44%), and minority positions in GN Store Nord, Pleo and Lineage Cell Therapeutics (ReSonance collaboration, 2025). Combined portfolio market value is approximately DKK 150 billion versus WDI's own DKK 60 billion market capitalization as of 2025.

The investment thesis targets innovation-driven companies in niche markets with unified product programs, global distribution, and demonstrated profitability (revenue threshold DKK 250 million plus stable cash flows). The company is wholly owned by the William Demant Foundation, with identical boards chaired by Lars Nørby Johansen and led as CEO by Niels Jacobsen. Total headcount across portfolio companies exceeds 35,000 worldwide, with products sold in more than 130 countries and operations in 30+ countries.

Name

William Demant Invest

Legal name

William Demant Invest A/S

Website

https://demantinvest.com

Company type

Private

Founded year

2004

Operating status

Operating

Short description

William Demant Invest A/S is a private Danish evergreen investment holding company, wholly owned by the William Demant Foundation. It holds majority and significant minority stakes in listed Nordic MedTech and healthcare companies spanning hearing healthcare, orthopaedics, radiation therapy, IVF, hematology, ophthalmology, and communications.

Ownership category

akta.pro rank

Product category

Investment Holding Company

NAICS

Management of Companies and Enterprises (551), Portfolio Management and Investment Advice (523940)

akta.pro primary industry

Industry-Specialist Buyout (Sector-Focused) (FSANABAE)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Evergreen investment company
• Healthcare portfolio holdings
• Medtech investment management
• Strategic investment holdings
• Foundation-owned investments

Headquarters

HQ city

Smørumnedre

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Investment Returns and Dividend Income: As an evergreen investment company, William Demant Invest generates returns through long-term ownership stakes in portfolio companies. The company holds majority and significant minority positions in listed companies across healthcare and MedTech sectors, with market capitalization growing from DKK 11 billion in 2004 to around DKK 60 billion in 2025.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

William Demant Invest is an evergreen investment holding company that maintains majority and significant minority ownership stakes in listed healthcare and MedTech companies. The company primarily holds 55-60% of Demant A/S (hearing healthcare), 51% of Embla Medical (non-invasive orthopaedics), and ~93% of Vision RT (radiation therapy), alongside significant minority positions in Vitrolife, CellaVision, Revenio, INVISIO, Jeudan, GN Store Nord, and Pleo.

Product overview

William Demant Invest is an evergreen investment company that serves as the holding company for William Demant Foundation's investment activities, focusing on investments in listed companies. The portfolio consists of strategic long-term investments in healthcare and medical technology companies, including Demant (hearing instruments and diagnostic equipment), Embla Medical (non-invasive orthopedics), Vision RT (surface guided radiation therapy), Vitrolife (IVF and reproductive treatment), CellaVision (digital hematology microscopy), Revenio (ophthalmology devices), INVISIO (advanced communication systems), Jeudan (real estate), and minority positions in GN Store Nord and Pleo. The total market value of the portfolio is approximately DKK 150 billion, with over 35,000 employees globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Demant A/S Strategic Investment Majority shareholding (55-60%) in Demant A/S, a leading global hearing healthcare company developing, manufacturing, and selling hearing instruments, diagnostic instruments and personal communication devices under brands including Oticon, Bernafon, Sonic, Maico, Interacoustics, Grason-Stadler, and EPOS. Products sold in more than 130 countries.
• Embla Medical Strategic Investment Majority shareholding (51%) in Embla Medical, a global leader in non-invasive orthopaedics focused on prosthetics and bracing/supports, with operations in 26 countries and approximately 4,000 employees.
• Vision RT Ltd. Strategic Investment Majority shareholding (~93%) in Vision RT Ltd., a UK-based pioneer and leading manufacturer of surface guided radiation therapy (SGRT) camera systems that improve efficiency, efficacy, and patient comfort during radiation therapy cancer treatment.
• Vitrolife AB Strategic Investment Significant minority shareholding (~30%) in Vitrolife AB, an international healthcare company providing medical equipment, consumables, and genetic testing services for IVF treatment, headquartered in Gothenburg, Sweden.
• CellaVision AB Strategic Investment Significant minority shareholding (~20%) in CellaVision AB, a global leader of digital solutions for medical microscopy in hematology, including analyzers, software, and applications for blood cell analysis.
• Revenio Oyj Strategic Investment Significant minority shareholding (~24%) in Revenio Oyj, which develops ophthalmological devices and software solutions (tonometers, fundus imaging, perimeters) under the iCare brand for early-stage detection of glaucoma, diabetic retinopathy, AMD, and cataract.
• INVISIO AB Strategic Investment Significant minority shareholding (20%) in INVISIO AB, a Danish company providing advanced communication systems, hearing protection, and intercom systems for professionals in noisy and mission-critical defense and security environments.
• Jeudan A/S Strategic Investment Significant minority shareholding (44%) in Jeudan A/S, Denmark's largest publicly listed real estate and service company, investing in and operating commercial and residential properties in Copenhagen.

Quantifiable outcome

• Market capitalization growth from DKK 11 billion (2004) to DKK 60 billion (2025)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Lineage Cell TherapeuticscoreStrategic or Co-development Partner · 1 January 2025William Demant Invest entered a collaboration with Lineage Cell Therapeutics for the ReSonance hearing loss program. Lineage Cell Therapeutics develops cell therapies for degenerative conditions, while William Demant Invest contributes investment and strategic expertise in hearing healthcare.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Investor AB: Swedish evergreen holding company with majority and minority positions in listed companies across healthcare, industrials, and technology. Closest structural analogue to WDI: permanent capital, sector-steward mindset, public-listed holdings model.
• Wendel: French family-controlled evergreen investment company with long-duration positions in listed and private companies. Comparable as a European permanent-capital holding entity with concentrated, long-held equity stakes.
• Wallenberg Investments (Knut and Alice Wallenberg Foundation): Swedish foundation-controlled investment complex holding major stakes in listed companies (Investor AB, Ericsson, Saab, etc.). Comparable as a Nordic foundation-owned evergreen capital model deploying patient capital into listed equities.
• Lundbergs: Swedish family-controlled evergreen investment company with concentrated holdings in Nordic listed companies. Closely comparable in being a multi-generational, permanent-capital vehicle with a focused portfolio of majority and significant minority stakes.
• Industrivärden: Swedish evergreen investment company with focused holdings in Nordic listed companies. Highly comparable in business model (active ownership in listed equities, long-term horizon) though more generalist in sector exposure.
• Novo Holdings: Danish foundation-owned (Novo Nordisk Foundation) holding and investment company with large healthcare/MedTech focus. Mirrors WDI's combination of foundation ownership, Nordic base, and long-duration capital deployed across life sciences.
• Kinnevik AB: Swedish evergreen investment company focused on consumer and healthcare technology. Similar long-duration ownership model and active engagement with portfolio companies, though heavier tilt toward growth-stage tech than WDI's mature MedTech.
• A.P. Møller Holding: Danish family/foundation-affiliated holding company controlling A.P. Møller-Mærsk and other listed assets. Highly comparable as a Danish, foundation-aligned, evergreen holding vehicle with concentrated ownership in listed operating companies.
• Exor N.V. European evergreen holding company (Agnelli family-controlled) with concentrated positions in large listed companies. Comparable as a permanent-capital, family/foundation-controlled holding entity with active governance and long-duration mandate.

Broad incumbents

• EQT AB: Large Swedish private equity firm with significant healthcare/MedTech franchise. Adjacent rather than directly comparable: EQT is fund-based (finite life) rather than evergreen, but it operates in the same Nordic healthcare investment space WDI targets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about William Demant Invest